Plain-English translation of NCT07282470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying special markers in blood and brain tumor tissue samples to develop a personalized test that can predict how meningiomas will behave after surgery. This test could help doctors tailor treatment plans to each patient's specific tumor and reduce the risk of the cancer coming back. The study will look at samples from patients who had surgery in the past, and also collect new samples from newly diagnosed patients.
Currently, doctors struggle to predict which meningioma patients will have their tumors return after surgery, making it hard to decide who needs additional treatment. This study aims to create a simple blood test that could answer these questions by reading the tumor's biological fingerprint, potentially changing how meningiomas are managed.
If you are in the retrospective group, researchers will use your stored tumor tissue and medical records from past surgery (no additional visits needed). If you are in the prospective group, you will have blood samples taken at specific times after your surgery, and researchers will use your tumor tissue from your operation. All samples are analyzed in the laboratory to develop the predictive test.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
Italy
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
University of Milan, Università degli Studi del Piemonte Orientale Amedeo Avogadro
Enrollment target
~210 participants
Started
September 2024
Primary completion
March 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.